右江医学2025，Vol.53Issue(6)：500-505,6.DOI:10.3969/j.issn.1003-1383.2025.06.004
特瑞普利单抗联合AP方案一线治疗手术不可切除的局部晚期非小细胞肺癌研究
A study on toripalimab combined with AP regimen as first-line treatment for surgically unresectable locally advanced non-small cell lung cancer
摘要
Abstract
Objective To observe the efficacy of toripalimab combined with AP regimen in the treatment of unresectable locally advanced non-small cell lung cancer(LA-NSCLC).Methods A total of 30 patients with unresectable LA-NSCLC who received AP regimen chemotherapy+conventional radiotherapy from October 2022 to May 2023 were enrolled as control group,while 32 patients who received toripalimab+AP regimen chemotherapy+conventional radiotherapy during the same period were included in observation group.The treatment was continued for 4 cycles.After treatment,a 2-month observation period was conducted to assess the efficacy.And then,immune functions before and after treatment,adverse reactions during the treatment period,and survival status during 1-year follow-up were statistically analyzed.Results Objective response rate(ORR)anddiseasecontrolrate(DCR)intheobservationgroupwere65.63%and93.75%,respectively,significantly higher than those in the control group(40.00%and 70.00%)(P<0.05).After 4 cycles of treatment,the levels of CD3+,CD4+,and the CD4+/CD8+ratio decreased compared to those before treatment in both groups.However,these indicators were higher in the observation group than in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions during the treatment period between the two groups(P>0.05).Median progression-free survival(PFS)and overall survival(OS)were longer in the observation group than in the control group(P<0.05).1-year survival rate was slightly higher in the observation group than in the control group,but difference in survival rates between the two groups was not statistically significant(P>0.05).Conclusion Toripalimab combined with AP regimen has a good overall therapeutic effect on unresectable LA-NSCLC,which can alleviate immune suppression caused by synchronous radio-therapy and chemotherapy.Although the short-term overall survival rate of patients has not significantly improved,the surviv-al time is prolonged and the safety is good.关键词
非小细胞肺癌/局部晚期/AP方案/特瑞普利单抗/免疫抑制/生存期Key words
non-small cell lung carcinoma(NSCLC)/locally advanced stage/AP regimen/toripalimab/immune suppression/survival period分类
医药卫生引用本文复制引用
丁文金,侯建平,张琪,柳家荣..特瑞普利单抗联合AP方案一线治疗手术不可切除的局部晚期非小细胞肺癌研究[J].右江医学,2025,53(6):500-505,6.基金项目
河南省医学科技攻关计划(联合共建)项目(LHGJ20220971) （联合共建）
